Answers are grounded in this paper and cite their sources.
Examines the immune response to a Rift Valley fever vaccine candidate in human monocytes, suggesting its potential for effective T cell activation.
The live-attenuated RVFV-4s vaccine against Rift Valley Fever has demonstrated safety and efficacy across multiple animal models and in a phase-I clinical trial. In this study, we examined its impact on innate immune responses and found that RVFV-4s enhances the expression of costimulatory molecules critical for T cell activation, while also triggering proinflammatory responses in primary human monocytes.
No takes yet. Share an insight, caveat, or question.
Nair et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: